

## ASX Announcement

### Strategic Commercial Partnership with Cancer Care Associates Accelerates Adoption of BREASTEST *plus*™

**Sydney, Australia – 3 July 2025** – BCAL Diagnostics Limited, (ASX: BDX, BCAL, the Company) an Australian biotechnology company pioneering non-invasive breast cancer diagnostics, today announced a strategic partnership with Cancer Care Associates (CCA), one of Australia’s leading private oncology networks with centres in New South Wales, Queensland and Western Australia.

Initially starting in Sydney, the collaboration is designed to accelerate the clinical uptake and validation with doctors of BREASTEST *plus*™, BCAL’s non-invasive, blood test that analyses lipids in the blood. BREASTEST *plus*™ complements mammography in existing breast cancer screening for women with dense breast tissue.

This agreement represents a significant commercial milestone for BCAL, establishing an additional pathway to market adoption and patient access through one of Australia’s most prominent oncology networks.

#### Key Highlights:

- **BREASTEST *plus*™ integrated into CCA’s clinical offering**, supporting uptake in both metropolitan and regional settings.
- **Revenue generation to commence in FY2026** through test distribution via CCA centres.
- **Accelerates BCAL’s real-world evidence and health economics data collection**, supporting discussions around reimbursement and further regulatory approvals.
- **Strengthens commercial rollout strategy**, positioning BCAL for broader national and potential international partnerships.
- **The partnership** will include a joint education and awareness campaign targeting healthcare providers and patients.

#### BCAL Diagnostics CEO, Shane Ryan, commented:

“This partnership marks an inflection point in BCAL’s early commercial journey and is a strong endorsement of the test’s clinical and commercial value. BCAL is focused on commercial growth through clinical and doctor partnerships and our agreement with CCA will continue to build clinical and patient awareness and expand patient access to BREASTEST*plus*™.”

#### Cancer Care Associates CEO, Damien Williams, added:

“We see BREASTEST *plus*™ as a valuable addition to our oncology ecosystem. This innovation supports our commitment to precision medicine and patient-centred care, and we look forward to working with BCAL to bring it to patients who need it most.”

This partnership is expected to provide initial revenue opportunities in FY2026, with expansion potential as clinical adoption grows. The collaboration showcases BCAL's position in strategic partner discussions, adding a critical validation layer to support long-term reimbursement outcomes.

Women are encouraged to speak with their doctor to see if BREASTEST *plus*<sup>™</sup> is right for them. Eligibility criteria apply.

Further information is available at [www.bcaldiagnostics.com](http://www.bcaldiagnostics.com). Alternatively, contact [info@bcaldiagnostics.com](mailto:info@bcaldiagnostics.com) or speak to a member of the BCAL support team regarding any questions related to BREASTEST *plus*<sup>™</sup> at 1300BCALDX (1300 222 539).

This announcement has been approved for release by the Board of BCAL Diagnostics Limited.

## ENDS

### For further information:

**Jayne Shaw**  
Executive Chair  
[Jshaw@bcaldiagnostics.com](mailto:Jshaw@bcaldiagnostics.com)

**Shane Ryan**  
Chief Executive Officer  
[Ryan@bcaldiagnostics.com](mailto:Ryan@bcaldiagnostics.com)

**Investor & Media Enquiries**  
Tanya Thomas  
Director Investor Relations &  
Communications  
[Tthomas@bcaldiagnostics.com](mailto:Tthomas@bcaldiagnostics.com)

### About BREASTEST *plus*<sup>™</sup>

BREASTEST *plus*<sup>™</sup> is the first product in BCAL's BREASTEST<sup>®</sup> range of non-invasive, lipid-based breast cancer diagnostics. BREASTEST *plus*<sup>™</sup> is a first in class blood test that measures a panel of lipids, using Liquid Chromatography Mass Spectrometry, to identify a lipidomic breast cancer signature. BREASTEST *plus*<sup>™</sup> is a 'rule-out' test that has been designed to be used in women with dense breasts and alongside mammography to improve screening and diagnostic outcomes for women.

### About BCAL Diagnostics

BCAL Diagnostics is an Australian and US-based biotechnology company dedicated to advancing early and accurate breast cancer detection. Our innovative, non-invasive blood test, the first in the BREASTEST<sup>®</sup> range of products is designed to complement existing breast screening methods and provide additional lipidomic insights to rule-out breast cancer, empowering women and their clinicians with greater confidence in diagnostic outcomes. Improved screening accuracy potentially reduces unnecessary follow-ups and enables timely intervention resulting in better health outcomes for women.

Founded in 2010, BCAL is headquartered in Sydney, AUS and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/> or contact [info@bcaldiagnostics.com](mailto:info@bcaldiagnostics.com).